PMV Pharmaceuticals, Inc. PMVP
We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the "guardian of the genome," and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function. We are deploying our precision oncology platform to target p53 mutations and other p53-related cancers.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| R&D | $69.9M | $58.5M | $55.9M | $52.0M | $36.5M | $23.9M | $20.8M | $13.9M | — |
| SG&A | $16.3M | $26.9M | $24.2M | $25.1M | $21.8M | $11.0M | $5.9M | $5.0M | — |
| Total operating expenses | $86.2M | $85.4M | $80.1M | $77.0M | $58.3M | $34.9M | $26.6M | $18.9M | — |
| Operating income | -$86.2M | -$85.4M | -$80.1M | -$77.0M | -$58.3M | -$34.9M | -$26.6M | -$18.9M | — |
| Interest expense | $6.3M | $10.7M | $11.2M | $3.6M | $449.0K | $651.0K | $1.3M | $1.3M | — |
| Pre-tax income | -$79.9M | -$74.8M | -$69.0M | -$73.3M | -$57.8M | -$34.4M | -$25.3M | -$17.5M | — |
| Income tax | $2.2M | $16.1M | $2.0K | $9.0K | $23.0K | $6.0K | $8.0K | $3.0K | — |
| Net income | -$77.7M | -$58.9M | -$69.0M | -$73.3M | -$57.8M | -$34.4M | -$25.4M | -$17.5M | — |
| EPS, basic | -1.48 | -1.14 | -1.44 | -1.61 | -1.28 | -2.40 | — | — | — |
| EPS, diluted | -1.48 | -1.14 | -1.44 | -1.61 | -1.28 | -2.40 | -8.35 | -5.82 | — |
| Shares, diluted (wtd. avg.) | 52.5M | 51.6M | 48.0M | 45.6M | 45.1M | 14.4M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $38.0M | $40.9M | $37.7M | $108.3M | $172.5M | $361.4M | $73.3M | — | — |
| Short-term investments | $75.0M | $128.6M | $165.4M | $132.8M | $124.7M | — | $28.2M | — | — |
| Total current assets | $115.2M | $175.7M | $207.4M | $247.0M | $301.3M | $364.8M | $102.1M | — | — |
| Property, plant and equipment | $237.0K | $409.0K | $10.7M | $11.0M | $3.1M | $569.0K | $739.0K | — | — |
| Total assets | $116.6M | $191.3M | $252.2M | $270.3M | $331.6M | $365.5M | $103.0M | — | — |
| Accounts payable | $3.2M | $6.6M | $3.2M | $3.0M | $3.2M | $1.6M | $2.8M | — | — |
| Total current liabilities | $11.4M | $14.4M | $14.0M | $10.8M | $12.2M | $6.4M | $4.5M | — | — |
| Total liabilities | $11.8M | $15.2M | $26.5M | $24.3M | $23.0M | $6.4M | $4.6M | — | — |
| Retained earnings | -$446.5M | -$368.7M | -$310.0M | -$241.0M | -$167.7M | -$109.9M | -$75.4M | — | — |
| Total equity | $104.7M | $176.1M | $225.7M | $246.0M | $308.6M | $359.1M | -$70.5M | -$46.1M | -$29.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$73.6M | -$51.3M | -$55.7M | -$63.8M | -$46.6M | -$32.7M | -$22.1M | -$15.2M | — |
| Depreciation and amortisation | $133.0K | $1.1M | $1.3M | $315.0K | $307.0K | $318.0K | $388.0K | $338.0K | — |
| Stock-based compensation | $5.9M | $8.9M | $12.4M | $10.2M | $5.3M | $1.9M | $908.0K | $1.1M | — |
| Capital expenditure | $29.0K | $655.0K | $962.0K | $8.0M | $1.3M | $148.0K | $109.0K | $452.0K | — |
| Investing cash flow | $70.2M | $53.4M | -$50.5M | -$1.4M | -$143.6M | $27.9M | $3.2M | $21.7M | — |
| Financing cash flow | $505.0K | $313.0K | $35.6M | $958.0K | $2.0M | $293.0M | $61.8M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-016038.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$17.5M | -$25.4M | -$34.4M | -$57.8M | -$73.3M | -$69.0M | -$58.9M | -$77.7M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |